We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 06, 2020

Effects of Once-Weekly Subcutaneous Semaglutide on Kidney Function and Safety in T2DM

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Effects of Once-Weekly Subcutaneous Semaglutide on Kidney Function and Safety in Patients With Type 2 Diabetes: A Post-Hoc Analysis of the SUSTAIN 1-7 Randomised Controlled Trials
Lancet Diabetes Endocrinol 2020 Sep 21;[EPub Ahead of Print], JFE Mann, T Hansen, T Idorn, LA Leiter, SP Marso, P Rossing, J Seufert, S Tadayon, T Vilsbøll

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading